FDAnews Drug Daily Bulletin

Drugmakers need to lobby against price controls in Medicare Part D that have an estimated price tag upward of $100 billion, amounting to a tax on the industry, incoming PhRMA Chair John Lechleiter says. Coupled with $150 billion in lost revenue from drugs entering the looming patent cliff, Medicare price controls could derail the development of 200 new medicines via reduced R&D spending, said Lechleiter, CEO of Eli Lilly.
Washington Drug Letter